Pharmaceutics· 2026Q1· Review
Chronic Spontaneous Urticaria in the Era of Targeted Therapy: From Pathogenic Mechanisms to Precision Medicine
- 0citations
- Q1SCImago
- 2026year
Short summary
Emerging targeted therapies like anti-IL-4Rα, BTK inhibitors (remibrutinib), and anti-c-KIT antibodies (barzolvolimab, briquilimab) show promise for chronic spontaneous urticaria (CSU), with some demonstrating rapid action, though endotype-specific efficacy and predictive biomarkers for treatment selection are still under investigation.
AI-generated from the title and abstract; the full text is not read.
TakeawaysIn the app
Key pointsIn the app
Ask the paperIn the app
The rest is in the Pofolia app
Takeaways, key points and questions to the paper; new summaries every day for your field. Free.
Sign in on the web to openField: Rheumatology
RheumatologyMedicine